VDA-1102 demonstrated strong inhibition of cancer growth across multiple indications.
70% of a panel with 57 cancer models (2019-2021)
Threshold <2uM; Colony forming assay in 57 patient-derived tumors and cancer cell lines conducted at Oncotest GmbH, a division of Charles River Labs.